Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glyburide (DiaBeta): a new second-generation hypoglycemic agent.

L P Krall

    Clinical Therapeutics
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diabetes in a New England town; a study of 3,516 persons in Oxford, Mass.

    Journal of the American Medical Association·2010
    Same author

    The history of diabetes lay associations.

    Patient education and counseling·1995
    Same author

    The gliclazide poster world in Lisbon, 1989.

    The American journal of medicine·1991
    Same author

    The treatment of NIDDM in the decade of the 90s.

    Diabetes research and clinical practice·1991
    Same author

    Wide, wide world of diabetes mellitus.

    The Diabetes educator·1986
    Same author

    The role of oral hypoglycemic agents in therapy and prevention of macrovascular complications.

    Hormone and metabolic research. Supplement series·1985

    Glyburide, a second-generation oral hypoglycemic, effectively manages non-insulin-dependent diabetes mellitus (NIDDM) with fewer side effects and lower doses than older drugs. Its unique prolonged action and safety profile expand treatment options for diabetes.

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Internal Medicine

    Background:

    • Non-insulin-dependent diabetes mellitus (NIDDM) management relies on oral hypoglycemic agents.
    • First-generation sulfonylureas have limitations in efficacy and dosage.
    • A need exists for safer and more effective NIDDM treatments.

    Purpose of the Study:

    • To evaluate glyburide as an improved therapeutic agent for NIDDM.
    • To compare glyburide's efficacy and safety with first-generation oral hypoglycemics.

    Main Methods:

    • Clinical evaluation of glyburide in NIDDM patients.
    • Pharmacokinetic and pharmacodynamic assessments.
    • Comparative analysis with existing oral hypoglycemic agents.

    Related Experiment Videos

    Main Results:

    • Glyburide demonstrates comparable or superior efficacy to first-generation agents at lower doses.
    • It possesses a unique prolonged action profile despite a short half-life.
    • Minimal side effects and no reported toxic reactions, with rare disulfiram-like or antidiuretic effects observed over 14 years of global use.

    Conclusions:

    • Glyburide offers a significant advancement in NIDDM management.
    • Its favorable safety profile and efficacy enhance the therapeutic options for diabetes.
    • This second-generation agent improves glycemic control by enhancing insulin sensitivity and utilization.